Tiziana Life Sciences Stock News

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has commenced site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple

NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said a study validating the mechanism of action of its drug candidate intranasal foralumab in Alzheimer's Disease has been published in the prestigious journal

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its investigational therapeutic foralumab will be highlighted by its scientific advisory board chairman Dr. Howard Weiner during an oral presentation at th

Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares added almost 55% in pre-market trading on Tuesday after the biotechnology company announced that its Investigational New Drug (IND) application for intra

Tiziana Life Sciences Ltd.'s stock TLSA soared 41% in premarket trade Tuesday, after the microcap biotech said it has received clearance from Food and Drug Administration for its investigational new d

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has appointed chief medical officer Dr Matthew Davis as its new chief operating officer. With the additional role, Tiziana said Davis will further dri

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced a significant update regarding non-active secondary progressive multiple sclerosis (SPMS) patients treated with h intranasal foralumab in the company'

Tiziana Life Sciences Ltd (NASDAQ:TLSA) reported promising in-depth findings on the utility of its lead candidate, intranasal foralumab, which is the only fully human anti-CD3 monoclonal antibody (mAb

Tiziana Life Sciences has updated investors on its lead programs in development along with the release of its financial results for the year ended December 31, 2022. The biotechnology company's interi

Tiziana Life Sciences Ltd (NASDAQ:TLSA) (Tiziana Life Sciences Ltd (NASDAQ:TLSA)) has announced the initiation of a program to develop intranasal Foralumab as a treatment or prevention method for type

Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trillion The role of activated microglia is well-established in the pathogenesis of Long COVID and Tiziana’s first-in-class intranasal foralumab dampens activated microglia NEW YORK, April 13, 2023 -- Tiziana Life Sciences Ltd.&nbs...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced plans to investigate intranasal foralumab for the treatment of Long COVID, work which is supported by foralumab's well-established role in de-acti

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that poster presentations on intranasal foralumab are being presented at the ‘Preserving the Brain' scientific conference and exhibit at the Fon

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported “exciting” pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody (mAb) in a model of intracerebral hemorrhage (hemorrhagi